摘要
目的挖掘藏医治疗肝胆疾病的用药规律,寻找核心药组,并预测核心药组的潜在靶点,以探讨核心药组治疗肝胆疾病的作用机制。方法收集藏医药典籍中治疗肝胆疾病处方,采用SPSS软件进行Apriori算法关联规则分析得到藏医治疗肝胆疾病的核心药组。检索中药系统药理学分析平台(TCMSP)、Therapeutic Target Database(TTD)、Genecards、Metascape等数据库进行基因本体(GO)和KEGG富集分析。结果共纳入607首方剂,数据挖掘得到藏医治疗肝胆疾病的核心药组为蒂达-洪连-波棱瓜子。收集到核心药组56个活性成分,作用于47个关键靶点,预测出1194条生物过程、49个细胞组成、54个分子功能以及226条信号通路。结论藏医在治疗肝胆疾病中主要以"清赤巴热"为核心,所使用方剂中的药物多以苦味为主;核心药组治疗肝胆疾病可能是通过缓解体内氧化应激、降低炎症表达以及调节胆汁酸肝肠循环等作用机制。
Objective To explore the law of Tibetan medicine treating liver and gallbladder diseases,look for core drug group,predict the potential targets of the core drug group,explore the mechanism action of core drug group in the treatment of liver and gallbladder diseases.Methods The prescriptions for the treatment of liver and gallbladder diseases which in Tibetan medical classical books were collected.SPSS software was used to analyze the association rules of Apriori algorithm,and eventually get the core drug groups about Tibetan medicine for the treatment of liver and gallbladder diseases.TCMSP,Symap,Genecards,TTD,Metascape and other databases were retrieved for Geneontology analysis and KEGG pathway enrichment.Results Totally 607 prescriptions were included,and the core drug group was Tida-Lagotidis Herb-Herpetospermum caudigerum.56 active ingredients,47 key targets with interactive relationship,1194 biological processes,49 cell components,54 molecular functions and 226 pathways were collected.ConclusionTibetan medicine in the treatment of liver and gallbladder diseases mainly focus on clear"chiba"fever.Involved drugsare mostly bitter taste;the mechanism about core group may be by relieving oxidative stress,reducing inflammatoryexpression and regulate the enterohepatic circulation of bile acid,so as to achieve the effect of treating liver andgallbladder diseases.
作者
宋鑫晨
李聪颖
刘紫轩
文成当智
余鹏
切尼项毛
久美彭措
张艺
Song Xinchen;Li Congying;Liu Zixuan;Wencheng Dangzhi;Yu Peng;Qieni Xiangmao;Jiumei Phuntsok;Zhang Yi(School of Ethnic Medicine,Chengdu University of Traditional Chinese Medicine,Chengdu 611137 China;School of Pharmacy,Qinghai Nationalities University,Xining 810007,China;School of Pharmacy,Chengdu University of Traditional Chinese Medicine,Chengdu 611137,China;Qinghai Jiumei Tibetan Medicine Company Limited,Xining 810003,China;Center for Academic Inheritance and Innovation of Ethnic Medicine,Chengdu University of Traditional Chinese Medicine,Chengdu 611137,China)
出处
《世界科学技术-中医药现代化》
CSCD
北大核心
2021年第5期1617-1626,共10页
Modernization of Traditional Chinese Medicine and Materia Medica-World Science and Technology
基金
国家科学技术部国家重点研发计划项目(2017YFC1703900):民族医药发掘整理与学术传承研究,负责人:张艺
国家自然科学基金委员会面上项目(81973573):基于BarHRM-电子舌-清‘赤巴’热效应指数的多基原藏药“蒂达”品质整合评控研究,负责人:张艺
青海省科技厅重点研发与转化专项(2020-SF-C33):藏药十五味赛尔斗丸的二次开发,负责人:久美彭措。
关键词
藏医药
肝胆疾病
APRIORI算法
网络药理学
用药规律
机制分析
胆汁酸
Tibetan medicine
Liver and gallbladder diseases
The Apriori algorithm
Network pharmacology
Prescription regularity
Mechanism analysis
Bile acid
